ArticleEuropean radiology2026
Design of the first national lung cancer screening program in the European Union: the Croatian Model.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Barriers and facilitators to population-based lung cancer screening in Belgium: a qualitative stakeholder analysis in a pre-implementation context.BMC health services research · 2026Article
- Is primary care the 'right care' for respiratory medicine in Africa?African journal of primary health care & family medicine · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo address Croatia's high lung cancer mortality and late-stage diagnoses, the Ministry of Health initiated a multidisciplinary effort to design a national lung cancer screening program. MATERIALS AND
methodsLung cancer remains one of the leading causes of cancer-related mortality both globally and in Croatia. In 2021 alone, Croatia recorded over 3300 new cases of lung cancer and more than 2800 associated deaths, indicating a high mortality burden. In response to this public health concern, the Ministry of Health has established a multidisciplinary Lung Cancer Screening Working Group, tasked with developing a national screening approach. The Program incorporates several innovative elements, including the application of modified International Early Lung Cancer Action Program (I-ELCAP) criteria for nodule management, volumetric analysis assessed by artificial intelligence, complete digitalization, smoking cessation, and nationwide deployment to ensure equitable access.
resultsFrom October 2020 to August 2025, over 50,000 participants were screened, resulting in more than 70,000 LDCT scans performed. The cohort includes 54% male and 46% female participants, with an average age of 62 years. Among these participants, 4.5% had positive results, which required further follow-up.
conclusionThe Croatian National Lung Cancer Screening Program offers unique features as it has been comprehensively incorporated into the existing healthcare infrastructure and is fully reimbursed. A key aspect of the program is the important role assigned to general practitioners (GPs), who are responsible for identifying and referring individuals at high risk for lung cancer. KEY POINTS: Question No European Union country has implemented a national lung cancer screening program despite evidence from previous trials showing significant mortality reduction. Findings Croatia successfully launched a fully integrated national lung cancer screening program using LDCT, AI-assisted volumetric analysis, modified I-ELCAP criteria, and GP-centered recruitment. Clinical relevance The Croatian model demonstrates the feasibility of national lung cancer screening within a European public healthcare system with full reimbursement, providing a replicable framework for other EU countries implementing lung cancer screening programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.